.svg){kind=small}
Randomised Phase III Trials With Large Patient Groups
We conduct randomised Phase III trials with large populations and a broad spectrum of therapy areas.
Our model is meticulously designed to cater to the specific requirements of our esteemed sponsors during the advanced stages of drug development.
Examples of Richmond’s accelerated patient recruitment
Leading the way among 83 centres, Richmond achieved top patient recruitment for a study focused on individuals with Transthyretin Amyloidosis with Cardiomyopathy, enrolling an impressive 64 patients within a three-month timeframe.
Richmond swiftly contributed to a global heart failure trial by successfully recruiting 10% of the total patient volunteers required within an exceptionally brief span of two months.
Experts In Conducting Randomised Phase III Clinical Trials.
Our specialist clinical team has experience in conducting clinical trials with a broad spectrum of patient groups with common and rare diseases.
Why Choose Richmond Pharmacology For Phase III Clinical Trials?
Single Centre Studies
We are equipped to deliver single centre studies for early phase patient trials.
Multi-disciplined teams
Through our strategic collaborations with academic institutions and medical organisations, we have established invaluable connections with a network of esteemed specialist consultants, professors, and skilled medical practitioners.
Hospital-style setting
.svg)
Our multi-disciplinary team operates in a hospital-style setting which facilitates efficient, safe trial management.
Hear from our sponsors
.svg){kind=small}
-min.jpg)
.jpg)
Latest news
Richmond Appoints Lisa Campbell as Director of Regulatory Strategy
Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
Events
Swiss Biotech Day 2025
